Infective endocarditis (IE) is a complex clinical condition in which approximately half of patients require surgical treatment during hospitalization, while the remaining patients are managed medically according to current guideline recommendations. However, limited evidence is available regarding the long-term management and outcomes of patients treated conservatively after completion of antibiotic therapy. The ENDOCARDITIS study is a multicenter, observational study with retrospective and prospective components designed to evaluate long-term outcomes in patients with definite infective endocarditis managed either surgically or with medical therapy alone. Adult patients will be enrolled and followed for up to 24 months. The primary objective is to compare long-term outcomes between surgical and non-surgical patients, while the secondary objective is to define optimal long-term follow-up strategies for patients treated medically.
Infective Endocarditis (IE) is a complex condition and not all patients require surgery. According to update guidelines, approximaly 50% of patients with IE require surgery during hospitalisation. The remaining 50% of patients are treated with medical therapy. ESC guidelines (2023) are very clear in defining the indication and timing of surgery in patients with IE: heart failure, risk of embolism and uncontrolled infection are clear indications for surgery in a short timeframe but, the decision making, should take into account not only the localisation and the extension of the infection, but also patient' s pre operative status and his comorbidities, as well as the mind status. In addition to patients excluded from surgery due to status and comorbidities, there is also a share of patients who do not meet the criteria for surgery. These patients can be treated with adequate IV antibiotic therapy and then with oral therapy.
Study Type
OBSERVATIONAL
Enrollment
1,046
Centro Cardiologico Monzino; IRCCS
Milan, Milan, Italy
Incidence of Major Adverse Clinical Events (MACE) During Follow-up
Proportion of participants experiencing at least one major adverse clinical event, defined as all-cause mortality, recurrent infective endocarditis (relapse or reinfection), hospitalization, systemic embolic event, or heart failure during follow-up. Events will be assessed through clinical evaluation and review of medical records.
Time frame: Baseline through 24-month follow-up
All-Cause Mortality During 24-Month Follow-up
Proportion of patients experiencing all-cause mortality during follow-up.
Time frame: Baseline through 24-month follow-up
Relapse or Reinfection of Infective Endocarditis During 24-Month Follow-up
Proportion of patients experiencing relapse or reinfection of infective endocarditis during follow-up.
Time frame: Baseline through 24-month follow-up
Hospitalization During 24-Month Follow-up
Proportion of patients experiencing hospitalization during follow-up
Time frame: Baseline through 24-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.